Clinical Trial Detail

NCT ID NCT02448303
Title Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

lung non-small cell carcinoma

Therapies

Acalabrutinib

Pembrolizumab

Age Groups: adult

No variant requirements are available.